Nikkei 225 Intelligence
2026-10-08 Astellas Pharma Inc. “Selected as the No. 1 company in the pharmaceutical sector of the " … 続きを読む
2026-10-07 Astellas Pharma Inc. “We will present data on our oncology portfolio and pipeline at the Euro … 続きを読む
2026-09-24 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated in pa … 続きを読む
2026-09-18 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorizat … 続きを読む
2026-09-01 Astellas Pharma Inc. “We have reached an agreement with the U.S. government to help improve a … 続きを読む
2026-08-27 Astellas Pharma Inc. “We have been appointed as a host city partner for the One Young World 2 … 続きを読む
2026-08-25 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated for A … 続きを読む
2026-08-07 Astellas Pharma Inc. “Fezolinent has been submitted for manufacturing and marketing approval … 続きを読む
2026-08-05 Astellas Pharma Inc. “First quarter financial results for fiscal year 2026.”
2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received a … 続きを読む